drugset / Trial / NCT00664664

Subjective Study to Assess the Efficacy of APD125 in Patients With Sleep Maintenance Insomnia

NCT00664664 ↗

Phase 2 Completed 744 enrolled Arena Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is designed to compare 2 doses of APD125 (20 mg and 40 mg) with placebo in otherwise healthy adults with primary insomnia primarily with complaints of maintaining sleep. Participants will be required to maintain a daily sleep dairy for up to 3 weeks while on study.

Timeline

Start
2008-04
Primary completion
2008-10
Completion
2008-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Nelotanserin Small molecule 20 mg —
Subject Nelotanserin Small molecule 40 mg —

Indications